SHR-A1811 + SHR-1316 + capecitabine

SHR-A1811 + SHR-1316 + capecitabine is an investigational combination therapy comprising two novel biologic agents and a standard chemotherapeutic. SHR-A1811 is an antibody-drug conjugate targeting Human epidermal growth factor receptor 2 (HER2), designed to deliver cytotoxic agents directly to HER2-expressing tumor cells, thereby enhancing antitumor efficacy while limiting systemic toxicity. It has demonstrated promising activity in advanced HER2-mutant non-small cell lung cancer and HER2-positive breast cancer[6][8]. SHR-1316, also known as adebrelimab, is a monoclonal antibody that targets Programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring T-cell mediated immune responses against tumors. It has shown efficacy in extensive-stage small cell lung cancer (ES-SCLC) and esophageal squamous cell carcinoma when combined with chemotherapy[3][4][5][7]. Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), a widely used small molecule chemotherapeutic agent that inhibits thymidylate synthase, disrupting DNA synthesis in rapidly dividing cells.

Other names

Adebrelimab (for SHR-1316)